

Amendments to the specification:

To page 1, line 2, after the title, please insert the following sentence:

-- This application is a Rule 371 U.S. National Phase Filing of PCT/EP05/000034, filed January 5, 2005, which, in turn, claims priority to European Patent Application No. 04.100053.0, filed January 9, 2004 and U.S. Provisional Patent Application Serial No. 60/535,674, filed January 9, 2004, the contents of which are incorporated by reference herein in their entirety. --

Please replace the first paragraph on page 8 with the following rewritten version:

-- The pharmaceutical compositions of the invention frequently comprise for each part by weight of a crystalline polymorphic form A 0.001 to 100 parts, preferably 0.01 to 10 parts, especially 0.05 to 2 parts by weight of a crystalline polymorphic form B. Of course, pharmaceutical compositions which contain pure polymorphic form A and pharmaceutical compositions which contain pure polymorphic form B of ~~Rizatriptan~~ Rizatriptan benzoate are also preferred. --